Inovio Pharmaceuticals Inc INO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Kuehn Law Encourages Investors of Inovio Pharmaceuticals, Inc. to Contact Law Firm
-
INOVIO to Participate in Upcoming Scientific and Investor Conferences
-
Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China
-
INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights
-
INOVIO to Participate in Upcoming Scientific Conferences
-
INOVIO to Report First Quarter Financial Results on May 13, 2026
-
Inovio Deadline Today: Rosen Law Firm Urges Inovio Pharmaceuticals, Inc. (NASDAQ: INO) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
-
INO CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals Investors of Securities Class Action Deadline on April 7, 2026
Trading Information
- Previous Close Price
- $1.09
- Day Range
- $1.06–1.11
- 52-Week Range
- $1.03–2.98
- Bid/Ask
- $1.10 / $1.13
- Shares Outstanding
- 82.27M
- Market Cap
- $90.50M
- Volume/Avg
- 224 / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 112
- Website
- https://www.inovio.com
Valuation
|
Metric
|
INO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 12.71 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
INO
|
|---|---|
Quick Ratio | 0.99 |
Current Ratio | 1.04 |
Interest Coverage | — |
Quick Ratio
INO
Profitability
|
Metric
|
INO
|
|---|---|
Return on Assets (Normalized) | −118.45% |
Return on Equity (Normalized) | −404.38% |
Return on Invested Capital (Normalized) | −278.27% |
Return on Assets
INO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Ybrblhhp | Zcggb | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Jtdflspw | Pfqmzh | $64B | |||
| argenx SE ADR
ARGX
| Hzgfbjql | Xflgs | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Rlwdlbj | Lchkzv | $39B | |||
| Royalty Pharma PLC Class A
RPRX
| Vktlpmfj | Lbggvsv | $24B | |||
| BioNTech SE ADR
BNTX
| Yzwxdzhyx | Wdh | $23B | |||
| Incyte Corp
INCY
| Lmmsvcnmw | Dmkxt | $22B | |||
| Moderna Inc
MRNA
| Wmvxkmnr | Xwkhv | $20B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Bcgjfkrt | Wyc | $15B | |||
| BridgeBio Pharma Inc
BBIO
| Rqkczqsvd | Jtbn | $13B |
United States